Table 5.

Unadjusted and adjusted HR estimates for risk of all-cause death according to urine biomarker (n=848 participants)

Urine Biomarker	Unadjusted HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
Urine NGAL/creatinine
Per log increase	1.38 (1.25 to 1.53)a	1.55 (1.36 to 1.76)a	1.44 (1.26 to 1.65)a
Quartile 1	Reference	Reference	Reference
Quartile 2	1.93 (1.25 to 2.97)a	2.19 (1.27 to 3.81)a	1.98 (1.13 to 3.45)a
Quartile 3	1.78 (1.15 to 2.73)a	1.73 (0.96 to 3.11)	1.55 (0.85 to 2.80)
Quartile 4	3.26 (2.15 to 4.95)a	4.08 (2.32 to 7.18)a	3.12 (1.73 to 5.64)a
Urine KIM-1/creatinine
Per log increase	1.53 (1.28 to 1.83)a	1.44 (1.16 to 1.78)a	1.29 (1.03 to 1.61)a
Quartile 1	Reference	Reference	Reference
Quartile 2	1.21 (0.79 to 1.86)	1.19 (0.71 to 2.02)	1.03 (0.60 to 1.74)
Quartile 3	1.64 (1.08 to 2.48)a	1.56 (0.93 to 2.60)	1.32 (0.79 to 2.21)
Quartile 4	2.51 (1.69 to 3.75)a	2.33 (1.41 to 3.86)a	1.76 (1.05 to 2.93)a
Urine IL-18/creatinine
Per log increase	1.21 (1.07 to 1.36)a	1.35 (1.14 to 1.61)a	1.25 (1.04 to 1.49)a
Quartile 1	Reference	Reference	Reference
Quartile 2	0.98 (0.65 to 1.46)	1.04 (0.62 to 1.74)	0.93 (0.55 to 1.57)
Quartile 3	1.25 (0.84 to 1.85)	1.85 (1.11 to 3.11)a	1.55 (0.91 to 2.65)
Quartile 4	1.72 (1.17 to 2.53)a	2.31 (1.30 to 4.08)a	1.77 (0.98 to 3.17)
Urine L-FABP/creatinine
Per log increase	1.33 (1.18 to 1.49)a	1.31 (1.14 to 1.51)a	1.12 (0.94 to 1.35)
Quartile 1	Reference	Reference	Reference
Quartile 2	0.98 (0.65 to 1.49)	0.78 (0.44 to 1.36)	0.69 (0.39 to 1.21)
Quartile 3	1.47 (0.99 to 2.19)	1.11 (0.66 to 1.86)	0.84 (0.49 to 1.43)
Quartile 4	1.93 (1.29 to 2.88)a	1.55 (0.93 to 2.57)	0.85 (0.47 to 1.53)

Model 1 was adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, and eGFR. Model 2 was adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, eGFR, and urine ACR.

^aChi-squared test: P<0.05.